Some challenges still exist with single-target B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies due to variable or negative BCMA expression, although they have yielded remarkable efficacy in relapsed or refractory multiple myeloma. We developed anti-BCMA/GPRC5D bispecific CARs to mitigate the limitations and potentiate the functions of CAR T cells.

中文翻译：

---

复发或难治性多发性骨髓瘤患者的抗 BCMA/GPRC5D 双特异性 CAR T 细胞：一项单臂、单中心、1 期试验


由于 BCMA 表达可变或阴性，单靶点 B 细胞成熟抗原 （BCMA） 嵌合抗原受体 （CAR） T 细胞疗法仍然存在一些挑战，尽管它们在复发或难治性多发性骨髓瘤中产生了显着的疗效。我们开发了抗 BCMA/GPRC5D 双特异性 CAR 来减轻 CAR T 细胞的局限性并增强其功能。